- Exact Sciences press release ( NASDAQ: EXAS ): Q4 GAAP EPS of -$0.72 beats by $0.11 .
- Revenue of $552.9M (+16.7% Y/Y) beats by $27.29M .
- Total fourth quarter revenue of $553 million, an increase of 17% or 28% excluding COVID-19 testing, with Screening revenue of $404 million and Precision Oncology revenue of $143 million
-
The company anticipates revenue of $2,265-$2,315 million ($2.29B consensus) during 2023, assuming:
- Screening revenue of $1,660-$1,690 million,
- Precision Oncology revenue of $600-$620 million, and
- COVID-19 testing revenue of $5 million
For further details see:
Exact Sciences GAAP EPS of -$0.72 beats by $0.11, revenue of $552.9M beats by $27.29M